MedPageToday People with postvaccine myocarditis did not share the typical mid-term complications associated with conventional myocarditis, based on a population-based study from France.
With 18-month follow-up of people who had been hospitalized for myocarditis during the COVID-19 pandemic, it appeared that composite clinical outcomes were more favorable if people had developed myocarditis soon after COVID-19 mRNA vaccination rather than conventional myocarditis (weighted HR 0.55, 95% CI 0.36-0.86).
Meanwhile, the risk of poor composite outcomes — counting hospital readmission for myopericarditis, other cardiovascular events, and all-cause death — was comparable between post-COVID-19 myocarditis and conventional myocarditis groups (weighted HR 1.04, 95% CI 0.70-1.52), according to Laura Semenzato, MSc, a statistician at Saint-Denis Cedex France in Paris, and colleagues. Continue reading
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.